Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Enterprise ValueMarket Capitalization

Immuneering (IMRX) Return on Capital Employed: 2021-2023

Historic Return on Capital Employed for Immuneering (IMRX) over the last 2 years, with Dec 2023 value amounting to -0.58%.

  • Immuneering's Return on Capital Employed fell 15.00% to -0.58% in Q4 2023 from the same period last year, while for Dec 2023 it was -0.58%, marking a year-over-year decrease of 15.00%. This contributed to the annual value of -0.56% for FY2023, which is 18.00% down from last year.
  • As of Q4 2023, Immuneering's Return on Capital Employed stood at -0.58%, which was down 18.01% from -0.49% recorded in Q3 2023.
  • Over the past 5 years, Immuneering's Return on Capital Employed peaked at -0.21% during Q4 2021, and registered a low of -0.58% during Q4 2023.
  • Moreover, its 3-year median value for Return on Capital Employed was -0.40% (2022), whereas its average is -0.39%.
  • Data for Immuneering's Return on Capital Employed shows a maximum YoY dropped of 23bps (in 2023) over the last 5 years.
  • Over the past 3 years, Immuneering's Return on Capital Employed (Quarterly) stood at -0.21% in 2021, then declined by 22bps to -0.43% in 2022, then declined by 15bps to -0.58% in 2023.
  • Its Return on Capital Employed was -0.58% in Q4 2023, compared to -0.49% in Q3 2023 and -0.50% in Q2 2023.